ResearcherAzienda Ospedaliero-Universitaria CareggiNo recent work listed
Francesco Di Costanzo
Matched on ORCID iD 0000-0002-6858-7827; OpenAlex author ID A5023215623. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 26
2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 2 papers
Papers 5
- Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
- Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine. Co-author DOI 10.3390/cancers15020416↗
- Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). Last author DOI 10.3390/curroncol28030164↗
- hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2015.28↗
- Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Co-author DOI 10.1016/j.dld.2013.09.020↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elisa Giommoni · 2 shared papers, 2021–2023 · strength 0.35
- Paper Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus G… DOI 10.3390/cancers15020416↗
- Paper Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Stu… DOI 10.3390/curroncol28030164↗
- Lorenzo Antonuzzo · 2 shared papers, 2021–2023 · strength 0.35
- Paper Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus G… DOI 10.3390/cancers15020416↗
- Paper Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Stu… DOI 10.3390/curroncol28030164↗
- Vanja Vaccaro · 1 shared paper, 2021 · strength 0.11
- Caterina Vivaldi · 1 shared paper, 2021 · strength 0.11
- Guido Giordano · 1 shared paper, 2021 · strength 0.11
- Evaristo Maiello · 1 shared paper, 2021 · strength 0.11
- Giampaolo Tortora · 1 shared paper, 2021 · strength 0.11
- Tiziana Pia Latiano · 1 shared paper, 2021 · strength 0.11
- Serena Pillozzi · 1 shared paper, 2021 · strength 0.11
- Sagar S. Manoli · 1 shared paper, 2015 · strength 0.04
- Lapo Bencini · 1 shared paper, 2015 · strength 0.04
- Domenico Borzomati · 1 shared paper, 2015 · strength 0.04
- Elena Lastraioli · 1 shared paper, 2015 · strength 0.04
- Angelica Sette · 1 shared paper, 2015 · strength 0.04
- Gennaro Nappo · 1 shared paper, 2015 · strength 0.04
- Daniele Santini · 1 shared paper, 2015 · strength 0.04
- Annarosa Arcangeli · 1 shared paper, 2015 · strength 0.04
- Roberto Coppola · 1 shared paper, 2015 · strength 0.04
- Roberto Labianca · 1 shared paper, 2014 · strength 0.03
- Stefania Mosconi · 1 shared paper, 2014 · strength 0.03
- Sandro Barni · 1 shared paper, 2014 · strength 0.03
- Rossana Berardi · 1 shared paper, 2014 · strength 0.03
- Luca Faloppi · 1 shared paper, 2014 · strength 0.03
- Giuseppe Tonini · 1 shared paper, 2014 · strength 0.03
- Michela Cinquini · 1 shared paper, 2014 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.